Overview

Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL).

Phase:

Phase 1

Details

Lead Sponsor:

Kite, A Gilead Company

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate